Study Shows Promise of Neoadjuvant Nivolumab in Treating ccRCC

Immunotherapy has been a game-changer in the treatment of various types of cancer, including clear cell renal cell carcinoma (ccRCC). A recent study conducted a prospective, phase I trial of neoadjuvant nivolumab, an immune checkpoint inhibitor, prior to nephrectomy in…